Skip to main content
ORGANOIDSCIENCES LTD. logo

ORGANOIDSCIENCES LTD. — Investor Relations & Filings

Ticker · 476040 ISIN · KR7476040001 KO Professional, scientific and technical activities
Open in API
Filings indexed 54 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country KR South Korea
Listing KO 476040

About ORGANOIDSCIENCES LTD.

https://organoidrx.com/en/

ORGANOIDSCIENCES LTD. is a biotechnology company specializing in organoid-based technologies for drug development and regenerative medicine. The company develops next-generation cell therapies and treatments for incurable diseases by creating three-dimensional cell cultures that replicate the structure and function of human organs. Its core offerings include an Organoid-Based Regenerative Therapeutics Platform to overcome the limitations of conventional therapies and an evaluation platform for assessing drug efficacy and toxicity, providing an alternative to animal models. Additionally, the company has developed the Polaris Platform for evaluating immunotherapy sensitivity. ORGANOIDSCIENCES aims to provide innovative solutions for precise and proactive care, shifting the paradigm in the therapeutics market.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항 (오가노이드 기반 재생치료제 및 약물 스크리닝 플랫폼 관련 기술도입 계약 체결)
Regulatory Filings Classification · 80% confidence The document is a regulatory disclosure announcing the execution of a significant technology licensing contract (“투자판단 관련 주요경영사항”), providing detailed terms, counterparties, and financial impact. It is not a full financial report, management change, capital raise, or earnings release, nor is it merely publication of an existing report. Therefore it falls into the fallback category for general regulatory announcements (RNS).
2026-06-02 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 90% confidence The document is clearly titled “분기보고서” covering the period 2026-01-01 to 2026-03-31 (the first quarter of fiscal 2026). It runs over 150,000 characters, contains substantive narrative and detailed financial statements (sales by segment, asset schedules, R&D costs, etc.), and is not merely an announcement or a link to a report. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
증권발행결과(자율공시) (제3자배정유상증자)
Capital/Financing Update Classification · 100% confidence The document is a short announcement about the results of a securities issuance, specifically a third-party allotment of convertible preferred shares. It includes details such as the number of shares issued, the amount raised, the board resolution date, and the payment date. The document is only 656 characters long and does not contain detailed financial statements or analysis. It is an announcement of a capital raising event rather than a full report. Therefore, it fits the category of Capital/Financing Update (CAP).
2026-05-07 Korean
증권발행결과(자율공시) (제1회차CB)
Capital/Financing Update Classification · 95% confidence The document is a short announcement about the issuance results of securities, specifically a private placement of convertible bonds (CB). It includes details such as the type of security, issuance method, amount, dates, and listing status. The document is brief (656 characters) and focuses on the outcome of a financing activity rather than a full financial report or detailed analysis. This fits the definition of a Capital/Financing Update (CAP) rather than a full report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2026-05-07 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 88% confidence The document is a Korean "주요사항보고서(유상증자결정)" (Major Event Report on resolution of a paid-in capital increase) filed with the Financial Services Commission/KRX. It contains detailed terms of a third-party allotment of new shares: types and numbers of shares, issue price, allotment method, conversion rights, call options, board resolutions, etc. This is an announcement of a share issuance and capital change rather than a full annual/interim report or earnings release. It fits the “Share Issue/Capital Change” category (SHA).
2026-04-30 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 94% confidence The document is a Korean ‘‘주요사항보고서’’ (Material Event Report) detailing the decision to issue 24 billion KRW of convertible bonds including full financing terms, put/call options, conversion price adjustment mechanisms, and list of investors. It is not a quarterly/annual report or regulatory publication notice, but a primary disclosure of a new debt‐financing/capital structure transaction. This fits the Capital/Financing Update category (CAP).
2026-04-29 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.